Mereo BioPharma Group plc

Director's Dealing • May 3, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0742Y

Mereo BioPharma Group plc

03 May 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of Director Dealing

London, May 03, 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on 01 May 2019, John Richard, Head of Corporate Development at Mereo BioPharma, purchased 3500 American Depositary Shares (ADSs) at a total price of USD5.077 per share.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

John Richard

2

Reason for the notification

a)

Position/status

Head of Corporate Development

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs)

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

Price(s)	Volume(s)
USD5.05 USD5.06 USD5.08 USD5.08 USD5.08 USD5.09 USD5.09 USD5.09	98 100 2723 100 100 126 127 126

d)

Aggregated information:  volume, Price

Aggregated volume: 3500

Aggregated price: USD5.077

e)

Date of the transaction

2019-05-01

f)

Place of the transaction

XNMS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHXXLFBKEFBBBB